KRAS and non-small cell lung carcinoma: In a study conducted by Arbour et al. (2018), co-occurring mutations in TP53 and KRAS were not significantly associated with survival, although KRAS/TP53 mutant NSCLC was the most common co-occurring mutation identified in this study cohort (Bollig-Fischer et al., 2015).